Last 12 months
Inside the activity.
0 purchase rows · 0 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 17, 2019 Filed Jun 19, 2019 21:50 UTC |
Freund John GordonDirector
|
GrantStock Option (right to buy Common Stock) · Derivative | 11,610 | $0.00 Strike: $11.12 | $0.00 |
DisclosureSEC source: 0001209191-19-038097 · doc4.xml · derivative · entry 1 Freund John Gordon · CIK 0001296771 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,610 Underlying: Common Stock · 11,610 shares Expires 2029-06-16 F1 · derivative.exercise_date: The option vests as to 1/12th of the total shares monthly, beginning on July 7, 2019, with 100% of the total shares vested and exercisable on June 7, 2020, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document |
| June 17, 2019 Filed Jun 19, 2019 17:52 UTC |
Petree Daniel HDirector
|
GrantStock Option (right to buy Common Stock) · Derivative | 11,610 | $0.00 Strike: $11.12 | $0.00 |
DisclosureSEC source: 0001209191-19-038102 · doc4.xml · derivative · entry 1 Petree Daniel H · CIK 0001294939 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,610 Underlying: Common Stock · 11,610 shares Expires 2029-06-16 F1 · derivative.exercise_date: The option vests as to 1/12th of the total shares monthly, beginning on July 7, 2019, with 100% of the total shares vested and exercisable on June 7, 2020, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document |
| June 17, 2019 Filed Jun 19, 2019 21:48 UTC |
Dybbs MichaelDirector
|
GrantStock Option (right to buy Common Stock) · Derivative | 11,610 | $0.00 Strike: $11.12 | $0.00 |
DisclosureSEC source: 0001209191-19-038094 · doc4.xml · derivative · entry 1 Dybbs Michael · CIK 0001601264 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,610 Underlying: Common Stock · 11,610 shares Expires 2029-06-16 F1 · derivative.exercise_date: The option vests as to 1/12th of the total shares monthly, beginning on July 7, 2019, with 100% of the total shares vested and exercisable on June 7, 2020, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document |
| June 17, 2019 Filed Jun 19, 2019 17:51 UTC |
JANNEY DANIELDirector
|
GrantStock Option (right to buy Common Stock) · Derivative | 11,610 | $0.00 Strike: $11.12 | $0.00 |
DisclosureSEC source: 0001209191-19-038100 · doc4.xml · derivative · entry 1 JANNEY DANIEL · CIK 0001198325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,610 Underlying: Common Stock · 11,610 shares Expires 2029-06-16 F1 · derivative.exercise_date: The option vests as to 1/12th of the total shares monthly, beginning on July 7, 2019, with 100% of the total shares vested and exercisable on June 7, 2020, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document |
| June 17, 2019 Filed Jun 19, 2019 21:55 UTC |
Sharp ShaliniDirector
|
GrantStock Option (right to buy Common Stock) · Derivative | 11,610 | $0.00 Strike: $11.12 | $0.00 |
DisclosureSEC source: 0001209191-19-038103 · doc4.xml · derivative · entry 1 Sharp Shalini · CIK 0001377202 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,610 Underlying: Common Stock · 11,610 shares Expires 2029-06-16 F1 · derivative.exercise_date: The option vests as to 1/12th of the total shares monthly, beginning on July 7, 2019, with 100% of the total shares vested and exercisable on June 7, 2020, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document |
| June 17, 2019 Filed Jun 19, 2019 21:51 UTC |
Lobacki Joseph MDirector
|
GrantStock Option (right to buy Common Stock) · Derivative | 11,610 | $0.00 Strike: $11.12 | $0.00 |
DisclosureSEC source: 0001209191-19-038101 · doc4.xml · derivative · entry 1 Lobacki Joseph M · CIK 0001536193 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,610 Underlying: Common Stock · 11,610 shares Expires 2029-06-16 F1 · derivative.exercise_date: The option vests as to 1/12th of the total shares monthly, beginning on July 7, 2019, with 100% of the total shares vested and exercisable on June 7, 2020, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document |
| February 12, 2019 Filed Feb 14, 2019 16:52 UTC |
Petree Daniel HDirector
|
Exercise / conversionStock Option (right to buy Common Stock) · Derivative | 3,030 | $0.00 Strike: $5.09 | $0.00 |
DisclosureSEC source: 0001209191-19-010244 · doc4.xml · derivative · entry 3 Petree Daniel H · CIK 0001294939 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,030 shares Expires 2019-03-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option is fully vested. Read SEC document |
| February 12, 2019 Filed Feb 14, 2019 16:52 UTC |
Petree Daniel HDirector
|
Exercise / conversionCommon Stock | 3,030 | $5.09 | $15,422.70 |
DisclosureSEC source: 0001209191-19-010244 · doc4.xml · nonDerivative · entry 1 Petree Daniel H · CIK 0001294939 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,030 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 29, 2019 Filed Jan 31, 2019 17:11 UTC |
Worsley StephenChief Business Officer
|
GrantStock Option (right to buy Common Stock) · Derivative | 30,000 | $0.00 Strike: $10.45 | $0.00 |
DisclosureSEC source: 0001209191-19-006208 · doc4.xml · derivative · entry 1 Worsley Stephen · CIK 0001753062 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2029-01-28 F1 · derivative.exercise_date: The option vests as to 2.0833% of the total shares monthly, beginning on February 28, 2019, with 100% of the total shares vested and exercisable on January 29, 2023, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document |
| January 29, 2019 Filed Jan 31, 2019 17:07 UTC |
Shabbir AnikChief Technical Ops. Officer
|
GrantStock Option (right to buy Common Stock) · Derivative | 35,000 | $0.00 Strike: $10.45 | $0.00 |
DisclosureSEC source: 0001209191-19-006201 · doc4.xml · derivative · entry 1 Shabbir Anik · CIK 0001751728 · Chief Technical Ops. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2029-01-28 F1 · derivative.exercise_date: The option vests as to 2.0833% of the total shares monthly, beginning on February 28, 2019, with 100% of the total shares vested and exercisable on January 29, 2023, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document |
| January 29, 2019 Filed Jan 31, 2019 17:07 UTC |
ALBINI EDWARD CCFO and Secretary
|
GrantStock Option (right to buy Common Stock) · Derivative | 47,500 | $0.00 Strike: $10.45 | $0.00 |
DisclosureSEC source: 0001209191-19-006200 · doc4.xml · derivative · entry 1 ALBINI EDWARD C · CIK 0001240014 · CFO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,500 Underlying: Common Stock · 47,500 shares Expires 2029-01-28 F1 · derivative.exercise_date: The option vests as to 2.0833% of the total shares monthly, beginning on February 28, 2019, with 100% of the total shares vested and exercisable on January 29, 2023, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document |
| January 29, 2019 Filed Jan 31, 2019 17:08 UTC |
FITZPATRICK LINDA AChief People & Comm. Officer
|
GrantStock Option (right to buy Common Stock) · Derivative | 30,000 | $0.00 Strike: $10.45 | $0.00 |
DisclosureSEC source: 0001209191-19-006202 · doc4.xml · derivative · entry 1 FITZPATRICK LINDA A · CIK 0001188953 · Chief People & Comm. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2029-01-28 F1 · derivative.exercise_date: The option vests as to 2.0833% of the total shares monthly, beginning on February 28, 2019, with 100% of the total shares vested and exercisable on January 29, 2023, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document |
| January 29, 2019 Filed Jan 31, 2019 17:11 UTC |
NEWELL WILLIAM JDirector · CEO
|
GrantStock Option (right to buy Common Stock) · Derivative | 445,000 | $0.00 Strike: $10.45 | $0.00 |
DisclosureSEC source: 0001209191-19-006206 · doc4.xml · derivative · entry 1 NEWELL WILLIAM J · CIK 0001309660 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 445,000 Underlying: Common Stock · 445,000 shares Expires 2029-01-28 F1 · derivative.exercise_date: The option vests as to 2.0833% of the total shares monthly, beginning on February 28, 2019, with 100% of the total shares vested and exercisable on January 29, 2023, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document |
| January 29, 2019 Filed Jan 31, 2019 17:08 UTC |
Hallam TrevorChief Science Officer
|
GrantStock Option (right to buy Common Stock) · Derivative | 47,500 | $0.00 Strike: $10.45 | $0.00 |
DisclosureSEC source: 0001209191-19-006203 · doc4.xml · derivative · entry 1 Hallam Trevor · CIK 0001326592 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,500 Underlying: Common Stock · 47,500 shares Expires 2029-01-28 F1 · derivative.exercise_date: The option vests as to 2.0833% of the total shares monthly, beginning on February 28, 2019, with 100% of the total shares vested and exercisable on January 29, 2023, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document |
| January 29, 2019 Filed Jan 31, 2019 22:09 UTC |
MOLINA ARTURO MDChief Medical Officer
|
GrantStock Option (right to buy Common Stock) · Derivative | 47,500 | $0.00 Strike: $10.45 | $0.00 |
DisclosureSEC source: 0001209191-19-006204 · doc4.xml · derivative · entry 1 MOLINA ARTURO MD · CIK 0001398940 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,500 Underlying: Common Stock · 47,500 shares Expires 2029-01-28 F1 · derivative.exercise_date: The option vests as to 2.0833% of the total shares monthly, beginning on February 28, 2019, with 100% of the total shares vested and exercisable on January 29, 2023, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document |
| November 08, 2018 Filed Nov 13, 2018 22:23 UTC |
Sharp ShaliniDirector
|
GrantStock Option (right to buy Common Stock) · Derivative | 26,033 | $0.00 Strike: $14.23 | $0.00 |
DisclosureSEC source: 0001209191-18-058335 · doc4.xml · derivative · entry 1 Sharp Shalini · CIK 0001377202 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,033 Underlying: Common Stock · 26,033 shares Expires 2028-11-07 F1 · derivative.exercise_date: The option vests as to 2.777% of the total shares monthly, beginning on December 7, 2018, with 100% of the total shares vested and exercisable on November 7, 2021, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document |
| October 01, 2018 Filed Oct 1, 2018 17:28 UTC |
SVLSF V, LLC10% owner
ILSF III, LLC10% owner
SV Life Sciences Fund V (GP), LP10% owner
SV LIFE SCIENCES FUND V LP10% owner
|
ConversionSeries E Preferred Stock · Derivative | 193,492 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-052851 · doc4.xml · derivative · entry 36 SVLSF V, LLC · CIK 0001644160 · 10% owner ILSF III, LLC · CIK 0001630791 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III (GP), L.P. · CIK 0001630790 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III STRATEGIC PARTNERS, L.P. · CIK 0001233226 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III CO-INVESTMENT, L.P. · CIK 0001233315 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III (LP1), L.P. · CIK 0001172861 · 10% owner SV Life Sciences Fund V (GP), LP · CIK 0001644146 · 10% owner SV LIFE SCIENCES FUND V LP · CIK 0001460732 · 10% owner SV Life Sciences Fund V Strategic Partners, L.P. · CIK 0001482194 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By SV Life Sciences Fund V Strategic Partners, L.P. Disclosed balance after: 0 Underlying: Common Stock · 5,320 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_price: Each share of the issuer's Series E Preferred Stock automatically converted into 0.0275 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date. F7 · derivative.exercise_date: Each share of the issuer's Series E Preferred Stock automatically converted into 0.0275 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date. F7 · derivative.expiration_date: Each share of the issuer's Series E Preferred Stock automatically converted into 0.0275 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date. F8 · ownership.nature: These shares are owned directly by SV Life Sciences Fund V Strategic Partners, L.P. ("SVLS V SPP"). SVLS V GP is the general partner of SVLS V SPP. The general partner of SVLS V GP is SVLSF V, LLC. Kate Bingham, James Garvey, Eugene D. Hill, III and Michael J. Ross are members of the investment committee of SVLSF V, LLC. SVLS V GP, SVLSF V, LLC and each of the individuals comprising the SVLSF V, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V SPP. Each of SVLS V GP, SVLSF V, LLC and the individual members of the SVLSF V, LLC investment committee disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein. Read SEC document |
| October 01, 2018 Filed Oct 1, 2018 17:28 UTC |
SVLSF V, LLC10% owner
ILSF III, LLC10% owner
SV Life Sciences Fund V (GP), LP10% owner
SV LIFE SCIENCES FUND V LP10% owner
|
ConversionSeries D Preferred Stock · Derivative | 141,249 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-052851 · doc4.xml · derivative · entry 35 SVLSF V, LLC · CIK 0001644160 · 10% owner ILSF III, LLC · CIK 0001630791 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III (GP), L.P. · CIK 0001630790 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III STRATEGIC PARTNERS, L.P. · CIK 0001233226 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III CO-INVESTMENT, L.P. · CIK 0001233315 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III (LP1), L.P. · CIK 0001172861 · 10% owner SV Life Sciences Fund V (GP), LP · CIK 0001644146 · 10% owner SV LIFE SCIENCES FUND V LP · CIK 0001460732 · 10% owner SV Life Sciences Fund V Strategic Partners, L.P. · CIK 0001482194 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By SV Life Sciences Fund V Strategic Partners, L.P. Disclosed balance after: 0 Underlying: Common Stock · 5,721 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_price: Each share of the issuer's Series D Preferred Stock automatically converted into 0.0405 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date. F6 · derivative.exercise_date: Each share of the issuer's Series D Preferred Stock automatically converted into 0.0405 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date. F6 · derivative.expiration_date: Each share of the issuer's Series D Preferred Stock automatically converted into 0.0405 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date. F8 · ownership.nature: These shares are owned directly by SV Life Sciences Fund V Strategic Partners, L.P. ("SVLS V SPP"). SVLS V GP is the general partner of SVLS V SPP. The general partner of SVLS V GP is SVLSF V, LLC. Kate Bingham, James Garvey, Eugene D. Hill, III and Michael J. Ross are members of the investment committee of SVLSF V, LLC. SVLS V GP, SVLSF V, LLC and each of the individuals comprising the SVLSF V, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V SPP. Each of SVLS V GP, SVLSF V, LLC and the individual members of the SVLSF V, LLC investment committee disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein. Read SEC document |
| October 01, 2018 Filed Oct 1, 2018 17:28 UTC |
SVLSF V, LLC10% owner
ILSF III, LLC10% owner
SV Life Sciences Fund V (GP), LP10% owner
SV LIFE SCIENCES FUND V LP10% owner
|
ConversionSeries C Preferred Stock · Derivative | 194,786 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-052851 · doc4.xml · derivative · entry 34 SVLSF V, LLC · CIK 0001644160 · 10% owner ILSF III, LLC · CIK 0001630791 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III (GP), L.P. · CIK 0001630790 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III STRATEGIC PARTNERS, L.P. · CIK 0001233226 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III CO-INVESTMENT, L.P. · CIK 0001233315 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III (LP1), L.P. · CIK 0001172861 · 10% owner SV Life Sciences Fund V (GP), LP · CIK 0001644146 · 10% owner SV LIFE SCIENCES FUND V LP · CIK 0001460732 · 10% owner SV Life Sciences Fund V Strategic Partners, L.P. · CIK 0001482194 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By SV Life Sciences Fund V Strategic Partners, L.P. Disclosed balance after: 0 Underlying: Common Stock · 7,207 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each share of the issuer's Series C Preferred Stock automatically converted into 0.0370 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date. F4 · derivative.exercise_date: Each share of the issuer's Series C Preferred Stock automatically converted into 0.0370 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date. F4 · derivative.expiration_date: Each share of the issuer's Series C Preferred Stock automatically converted into 0.0370 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date. F8 · ownership.nature: These shares are owned directly by SV Life Sciences Fund V Strategic Partners, L.P. ("SVLS V SPP"). SVLS V GP is the general partner of SVLS V SPP. The general partner of SVLS V GP is SVLSF V, LLC. Kate Bingham, James Garvey, Eugene D. Hill, III and Michael J. Ross are members of the investment committee of SVLSF V, LLC. SVLS V GP, SVLSF V, LLC and each of the individuals comprising the SVLSF V, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V SPP. Each of SVLS V GP, SVLSF V, LLC and the individual members of the SVLSF V, LLC investment committee disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein. Read SEC document |
| October 01, 2018 Filed Oct 1, 2018 17:28 UTC |
SVLSF V, LLC10% owner
ILSF III, LLC10% owner
SV Life Sciences Fund V (GP), LP10% owner
SV LIFE SCIENCES FUND V LP10% owner
|
ConversionSeries E Preferred Stock · Derivative | 9,155,794 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-052851 · doc4.xml · derivative · entry 33 SVLSF V, LLC · CIK 0001644160 · 10% owner ILSF III, LLC · CIK 0001630791 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III (GP), L.P. · CIK 0001630790 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III STRATEGIC PARTNERS, L.P. · CIK 0001233226 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III CO-INVESTMENT, L.P. · CIK 0001233315 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III (LP1), L.P. · CIK 0001172861 · 10% owner SV Life Sciences Fund V (GP), LP · CIK 0001644146 · 10% owner SV LIFE SCIENCES FUND V LP · CIK 0001460732 · 10% owner SV Life Sciences Fund V Strategic Partners, L.P. · CIK 0001482194 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By SV Life Sciences Fund V, L.P. Disclosed balance after: 0 Underlying: Common Stock · 251,783 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_price: Each share of the issuer's Series E Preferred Stock automatically converted into 0.0275 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date. F7 · derivative.exercise_date: Each share of the issuer's Series E Preferred Stock automatically converted into 0.0275 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date. F7 · derivative.expiration_date: Each share of the issuer's Series E Preferred Stock automatically converted into 0.0275 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date. F5 · ownership.nature: These shares are owned directly by SV Life Sciences Fund V, L.P. ("SVLS V LP"). SV Life Sciences Fund V (GP), LP ("SVLS V GP") is the general partner of SVLS V LP. The general partner of SVLS V GP is SVLSF V, LLC. Kate Bingham, James Garvey, Eugene D. Hill, III and Michael J. Ross are members of the investment committee of SVLSF V, LLC. SVLS V GP, SVLSF V, LLC and each of the individuals comprising the SVLSF V, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V LP. Each of SVLS V GP, SVLSF V, LLC and the individual members of the SVLSF V, LLC investment committee disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein. Read SEC document |
| October 01, 2018 Filed Oct 1, 2018 17:28 UTC |
SVLSF V, LLC10% owner
ILSF III, LLC10% owner
SV Life Sciences Fund V (GP), LP10% owner
SV LIFE SCIENCES FUND V LP10% owner
|
ConversionSeries D Preferred Stock · Derivative | 6,683,697 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-052851 · doc4.xml · derivative · entry 32 SVLSF V, LLC · CIK 0001644160 · 10% owner ILSF III, LLC · CIK 0001630791 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III (GP), L.P. · CIK 0001630790 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III STRATEGIC PARTNERS, L.P. · CIK 0001233226 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III CO-INVESTMENT, L.P. · CIK 0001233315 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III (LP1), L.P. · CIK 0001172861 · 10% owner SV Life Sciences Fund V (GP), LP · CIK 0001644146 · 10% owner SV LIFE SCIENCES FUND V LP · CIK 0001460732 · 10% owner SV Life Sciences Fund V Strategic Partners, L.P. · CIK 0001482194 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By SV Life Sciences Fund V, L.P. Disclosed balance after: 0 Underlying: Common Stock · 270,690 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_price: Each share of the issuer's Series D Preferred Stock automatically converted into 0.0405 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date. F6 · derivative.exercise_date: Each share of the issuer's Series D Preferred Stock automatically converted into 0.0405 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date. F6 · derivative.expiration_date: Each share of the issuer's Series D Preferred Stock automatically converted into 0.0405 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date. F5 · ownership.nature: These shares are owned directly by SV Life Sciences Fund V, L.P. ("SVLS V LP"). SV Life Sciences Fund V (GP), LP ("SVLS V GP") is the general partner of SVLS V LP. The general partner of SVLS V GP is SVLSF V, LLC. Kate Bingham, James Garvey, Eugene D. Hill, III and Michael J. Ross are members of the investment committee of SVLSF V, LLC. SVLS V GP, SVLSF V, LLC and each of the individuals comprising the SVLSF V, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V LP. Each of SVLS V GP, SVLSF V, LLC and the individual members of the SVLSF V, LLC investment committee disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein. Read SEC document |
| October 01, 2018 Filed Oct 1, 2018 17:28 UTC |
SVLSF V, LLC10% owner
ILSF III, LLC10% owner
SV Life Sciences Fund V (GP), LP10% owner
SV LIFE SCIENCES FUND V LP10% owner
|
ConversionSeries C Preferred Stock · Derivative | 9,217,015 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-052851 · doc4.xml · derivative · entry 31 SVLSF V, LLC · CIK 0001644160 · 10% owner ILSF III, LLC · CIK 0001630791 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III (GP), L.P. · CIK 0001630790 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III STRATEGIC PARTNERS, L.P. · CIK 0001233226 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III CO-INVESTMENT, L.P. · CIK 0001233315 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III (LP1), L.P. · CIK 0001172861 · 10% owner SV Life Sciences Fund V (GP), LP · CIK 0001644146 · 10% owner SV LIFE SCIENCES FUND V LP · CIK 0001460732 · 10% owner SV Life Sciences Fund V Strategic Partners, L.P. · CIK 0001482194 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By SV Life Sciences Fund V, L.P. Disclosed balance after: 0 Underlying: Common Stock · 341,030 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each share of the issuer's Series C Preferred Stock automatically converted into 0.0370 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date. F4 · derivative.exercise_date: Each share of the issuer's Series C Preferred Stock automatically converted into 0.0370 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date. F4 · derivative.expiration_date: Each share of the issuer's Series C Preferred Stock automatically converted into 0.0370 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date. F5 · ownership.nature: These shares are owned directly by SV Life Sciences Fund V, L.P. ("SVLS V LP"). SV Life Sciences Fund V (GP), LP ("SVLS V GP") is the general partner of SVLS V LP. The general partner of SVLS V GP is SVLSF V, LLC. Kate Bingham, James Garvey, Eugene D. Hill, III and Michael J. Ross are members of the investment committee of SVLSF V, LLC. SVLS V GP, SVLSF V, LLC and each of the individuals comprising the SVLSF V, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V LP. Each of SVLS V GP, SVLSF V, LLC and the individual members of the SVLSF V, LLC investment committee disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein. Read SEC document |
| October 01, 2018 Filed Oct 1, 2018 17:28 UTC |
SVLSF V, LLC10% owner
ILSF III, LLC10% owner
SV Life Sciences Fund V (GP), LP10% owner
SV LIFE SCIENCES FUND V LP10% owner
|
ConversionSeries C Preferred Stock · Derivative | 52,183 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-052851 · doc4.xml · derivative · entry 30 SVLSF V, LLC · CIK 0001644160 · 10% owner ILSF III, LLC · CIK 0001630791 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III (GP), L.P. · CIK 0001630790 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III STRATEGIC PARTNERS, L.P. · CIK 0001233226 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III CO-INVESTMENT, L.P. · CIK 0001233315 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III (LP1), L.P. · CIK 0001172861 · 10% owner SV Life Sciences Fund V (GP), LP · CIK 0001644146 · 10% owner SV LIFE SCIENCES FUND V LP · CIK 0001460732 · 10% owner SV Life Sciences Fund V Strategic Partners, L.P. · CIK 0001482194 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By International Life Sciences Fund III Strategic Partners, L.P. Disclosed balance after: 0 Underlying: Common Stock · 1,931 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each share of the issuer's Series C Preferred Stock automatically converted into 0.0370 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date. F4 · derivative.exercise_date: Each share of the issuer's Series C Preferred Stock automatically converted into 0.0370 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date. F4 · derivative.expiration_date: Each share of the issuer's Series C Preferred Stock automatically converted into 0.0370 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date. F2 · ownership.nature: International Life Sciences Fund III (GP), LP. ("Fund III GP") is the general partner of each of: (i) International Life Sciences Fund III (LP1), L.P. ("ILSF LP1"), (ii) International Life Sciences Fund III Co-Investment, L.P. ("ILSF Co-Invest") and (iii) International Life Sciences Fund III Strategic Partners, L.P. ("ILSF Strategic" and collectively, the "Fund III Entities"). ILSF III, LLC (the "ILSF General Partner") is the general partner of Fund III GP and, through an investment committee comprised of James Garvey, Kate Bingham, Eugene D. Hill, III and Michael J. Ross controls voting and investment decisions over the Issuer's shares held by the Fund III Entities by majority vote. Each of Fund III GP, ILSF General Partner, and each member of the investment committee of ILSF General Partner disclaims beneficial ownership over the Shares held by the Fund III Entities except to the extent of any pecuniary interest therein. Read SEC document |
| October 01, 2018 Filed Oct 1, 2018 17:28 UTC |
SVLSF V, LLC10% owner
ILSF III, LLC10% owner
SV Life Sciences Fund V (GP), LP10% owner
SV LIFE SCIENCES FUND V LP10% owner
|
ConversionSeries B Preferred Stock · Derivative | 106,019 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-052851 · doc4.xml · derivative · entry 29 SVLSF V, LLC · CIK 0001644160 · 10% owner ILSF III, LLC · CIK 0001630791 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III (GP), L.P. · CIK 0001630790 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III STRATEGIC PARTNERS, L.P. · CIK 0001233226 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III CO-INVESTMENT, L.P. · CIK 0001233315 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III (LP1), L.P. · CIK 0001172861 · 10% owner SV Life Sciences Fund V (GP), LP · CIK 0001644146 · 10% owner SV LIFE SCIENCES FUND V LP · CIK 0001460732 · 10% owner SV Life Sciences Fund V Strategic Partners, L.P. · CIK 0001482194 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By International Life Sciences Fund III Strategic Partners, L.P. Disclosed balance after: 0 Underlying: Common Stock · 6,128 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each share of the issuer's Series B Preferred Stock automatically converted into 0.0578 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date. F3 · derivative.exercise_date: Each share of the issuer's Series B Preferred Stock automatically converted into 0.0578 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date. F3 · derivative.expiration_date: Each share of the issuer's Series B Preferred Stock automatically converted into 0.0578 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date. F2 · ownership.nature: International Life Sciences Fund III (GP), LP. ("Fund III GP") is the general partner of each of: (i) International Life Sciences Fund III (LP1), L.P. ("ILSF LP1"), (ii) International Life Sciences Fund III Co-Investment, L.P. ("ILSF Co-Invest") and (iii) International Life Sciences Fund III Strategic Partners, L.P. ("ILSF Strategic" and collectively, the "Fund III Entities"). ILSF III, LLC (the "ILSF General Partner") is the general partner of Fund III GP and, through an investment committee comprised of James Garvey, Kate Bingham, Eugene D. Hill, III and Michael J. Ross controls voting and investment decisions over the Issuer's shares held by the Fund III Entities by majority vote. Each of Fund III GP, ILSF General Partner, and each member of the investment committee of ILSF General Partner disclaims beneficial ownership over the Shares held by the Fund III Entities except to the extent of any pecuniary interest therein. Read SEC document |
| October 01, 2018 Filed Oct 1, 2018 17:28 UTC |
SVLSF V, LLC10% owner
ILSF III, LLC10% owner
SV Life Sciences Fund V (GP), LP10% owner
SV LIFE SCIENCES FUND V LP10% owner
|
ConversionSeries A Preferred Stock · Derivative | 17,533 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-052851 · doc4.xml · derivative · entry 28 SVLSF V, LLC · CIK 0001644160 · 10% owner ILSF III, LLC · CIK 0001630791 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III (GP), L.P. · CIK 0001630790 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III STRATEGIC PARTNERS, L.P. · CIK 0001233226 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III CO-INVESTMENT, L.P. · CIK 0001233315 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III (LP1), L.P. · CIK 0001172861 · 10% owner SV Life Sciences Fund V (GP), LP · CIK 0001644146 · 10% owner SV LIFE SCIENCES FUND V LP · CIK 0001460732 · 10% owner SV Life Sciences Fund V Strategic Partners, L.P. · CIK 0001482194 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By International Life Sciences Fund III Strategic Partners, L.P. Disclosed balance after: 0 Underlying: Common Stock · 758 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of the issuer's Series A Preferred Stock automatically converted into 0.0433 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its firm commitment initial public offering (the "IPO") pursuant to a registration statement on Form S-1 (File No. 333-227103) under the Securities Act of 1933, as amended (the "Registration Statement"), and had no expiration date. F1 · derivative.exercise_date: Each share of the issuer's Series A Preferred Stock automatically converted into 0.0433 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its firm commitment initial public offering (the "IPO") pursuant to a registration statement on Form S-1 (File No. 333-227103) under the Securities Act of 1933, as amended (the "Registration Statement"), and had no expiration date. F1 · derivative.expiration_date: Each share of the issuer's Series A Preferred Stock automatically converted into 0.0433 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its firm commitment initial public offering (the "IPO") pursuant to a registration statement on Form S-1 (File No. 333-227103) under the Securities Act of 1933, as amended (the "Registration Statement"), and had no expiration date. F2 · ownership.nature: International Life Sciences Fund III (GP), LP. ("Fund III GP") is the general partner of each of: (i) International Life Sciences Fund III (LP1), L.P. ("ILSF LP1"), (ii) International Life Sciences Fund III Co-Investment, L.P. ("ILSF Co-Invest") and (iii) International Life Sciences Fund III Strategic Partners, L.P. ("ILSF Strategic" and collectively, the "Fund III Entities"). ILSF III, LLC (the "ILSF General Partner") is the general partner of Fund III GP and, through an investment committee comprised of James Garvey, Kate Bingham, Eugene D. Hill, III and Michael J. Ross controls voting and investment decisions over the Issuer's shares held by the Fund III Entities by majority vote. Each of Fund III GP, ILSF General Partner, and each member of the investment committee of ILSF General Partner disclaims beneficial ownership over the Shares held by the Fund III Entities except to the extent of any pecuniary interest therein. Read SEC document |
| October 01, 2018 Filed Oct 1, 2018 17:28 UTC |
SVLSF V, LLC10% owner
ILSF III, LLC10% owner
SV Life Sciences Fund V (GP), LP10% owner
SV LIFE SCIENCES FUND V LP10% owner
|
ConversionSeries C Preferred Stock · Derivative | 5,462,550 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-052851 · doc4.xml · derivative · entry 27 SVLSF V, LLC · CIK 0001644160 · 10% owner ILSF III, LLC · CIK 0001630791 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III (GP), L.P. · CIK 0001630790 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III STRATEGIC PARTNERS, L.P. · CIK 0001233226 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III CO-INVESTMENT, L.P. · CIK 0001233315 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III (LP1), L.P. · CIK 0001172861 · 10% owner SV Life Sciences Fund V (GP), LP · CIK 0001644146 · 10% owner SV LIFE SCIENCES FUND V LP · CIK 0001460732 · 10% owner SV Life Sciences Fund V Strategic Partners, L.P. · CIK 0001482194 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By International Life Sciences Fund III (LP1), L.P. Disclosed balance after: 0 Underlying: Common Stock · 202,115 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each share of the issuer's Series C Preferred Stock automatically converted into 0.0370 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date. F4 · derivative.exercise_date: Each share of the issuer's Series C Preferred Stock automatically converted into 0.0370 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date. F4 · derivative.expiration_date: Each share of the issuer's Series C Preferred Stock automatically converted into 0.0370 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date. F2 · ownership.nature: International Life Sciences Fund III (GP), LP. ("Fund III GP") is the general partner of each of: (i) International Life Sciences Fund III (LP1), L.P. ("ILSF LP1"), (ii) International Life Sciences Fund III Co-Investment, L.P. ("ILSF Co-Invest") and (iii) International Life Sciences Fund III Strategic Partners, L.P. ("ILSF Strategic" and collectively, the "Fund III Entities"). ILSF III, LLC (the "ILSF General Partner") is the general partner of Fund III GP and, through an investment committee comprised of James Garvey, Kate Bingham, Eugene D. Hill, III and Michael J. Ross controls voting and investment decisions over the Issuer's shares held by the Fund III Entities by majority vote. Each of Fund III GP, ILSF General Partner, and each member of the investment committee of ILSF General Partner disclaims beneficial ownership over the Shares held by the Fund III Entities except to the extent of any pecuniary interest therein. Read SEC document |
| October 01, 2018 Filed Oct 1, 2018 17:28 UTC |
SVLSF V, LLC10% owner
ILSF III, LLC10% owner
SV Life Sciences Fund V (GP), LP10% owner
SV LIFE SCIENCES FUND V LP10% owner
|
ConversionSeries B Preferred Stock · Derivative | 11,097,596 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-052851 · doc4.xml · derivative · entry 26 SVLSF V, LLC · CIK 0001644160 · 10% owner ILSF III, LLC · CIK 0001630791 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III (GP), L.P. · CIK 0001630790 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III STRATEGIC PARTNERS, L.P. · CIK 0001233226 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III CO-INVESTMENT, L.P. · CIK 0001233315 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III (LP1), L.P. · CIK 0001172861 · 10% owner SV Life Sciences Fund V (GP), LP · CIK 0001644146 · 10% owner SV LIFE SCIENCES FUND V LP · CIK 0001460732 · 10% owner SV Life Sciences Fund V Strategic Partners, L.P. · CIK 0001482194 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By International Life Sciences Fund III (LP1), L.P. Disclosed balance after: 0 Underlying: Common Stock · 641,440 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each share of the issuer's Series B Preferred Stock automatically converted into 0.0578 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date. F3 · derivative.exercise_date: Each share of the issuer's Series B Preferred Stock automatically converted into 0.0578 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date. F3 · derivative.expiration_date: Each share of the issuer's Series B Preferred Stock automatically converted into 0.0578 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date. F2 · ownership.nature: International Life Sciences Fund III (GP), LP. ("Fund III GP") is the general partner of each of: (i) International Life Sciences Fund III (LP1), L.P. ("ILSF LP1"), (ii) International Life Sciences Fund III Co-Investment, L.P. ("ILSF Co-Invest") and (iii) International Life Sciences Fund III Strategic Partners, L.P. ("ILSF Strategic" and collectively, the "Fund III Entities"). ILSF III, LLC (the "ILSF General Partner") is the general partner of Fund III GP and, through an investment committee comprised of James Garvey, Kate Bingham, Eugene D. Hill, III and Michael J. Ross controls voting and investment decisions over the Issuer's shares held by the Fund III Entities by majority vote. Each of Fund III GP, ILSF General Partner, and each member of the investment committee of ILSF General Partner disclaims beneficial ownership over the Shares held by the Fund III Entities except to the extent of any pecuniary interest therein. Read SEC document |
| October 01, 2018 Filed Oct 1, 2018 17:28 UTC |
SVLSF V, LLC10% owner
ILSF III, LLC10% owner
SV Life Sciences Fund V (GP), LP10% owner
SV LIFE SCIENCES FUND V LP10% owner
|
ConversionSeries A Preferred Stock · Derivative | 1,835,270 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-052851 · doc4.xml · derivative · entry 25 SVLSF V, LLC · CIK 0001644160 · 10% owner ILSF III, LLC · CIK 0001630791 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III (GP), L.P. · CIK 0001630790 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III STRATEGIC PARTNERS, L.P. · CIK 0001233226 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III CO-INVESTMENT, L.P. · CIK 0001233315 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III (LP1), L.P. · CIK 0001172861 · 10% owner SV Life Sciences Fund V (GP), LP · CIK 0001644146 · 10% owner SV LIFE SCIENCES FUND V LP · CIK 0001460732 · 10% owner SV Life Sciences Fund V Strategic Partners, L.P. · CIK 0001482194 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By International Life Sciences Fund III (LP1), L.P. Disclosed balance after: 0 Underlying: Common Stock · 79,467 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of the issuer's Series A Preferred Stock automatically converted into 0.0433 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its firm commitment initial public offering (the "IPO") pursuant to a registration statement on Form S-1 (File No. 333-227103) under the Securities Act of 1933, as amended (the "Registration Statement"), and had no expiration date. F1 · derivative.exercise_date: Each share of the issuer's Series A Preferred Stock automatically converted into 0.0433 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its firm commitment initial public offering (the "IPO") pursuant to a registration statement on Form S-1 (File No. 333-227103) under the Securities Act of 1933, as amended (the "Registration Statement"), and had no expiration date. F1 · derivative.expiration_date: Each share of the issuer's Series A Preferred Stock automatically converted into 0.0433 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its firm commitment initial public offering (the "IPO") pursuant to a registration statement on Form S-1 (File No. 333-227103) under the Securities Act of 1933, as amended (the "Registration Statement"), and had no expiration date. F2 · ownership.nature: International Life Sciences Fund III (GP), LP. ("Fund III GP") is the general partner of each of: (i) International Life Sciences Fund III (LP1), L.P. ("ILSF LP1"), (ii) International Life Sciences Fund III Co-Investment, L.P. ("ILSF Co-Invest") and (iii) International Life Sciences Fund III Strategic Partners, L.P. ("ILSF Strategic" and collectively, the "Fund III Entities"). ILSF III, LLC (the "ILSF General Partner") is the general partner of Fund III GP and, through an investment committee comprised of James Garvey, Kate Bingham, Eugene D. Hill, III and Michael J. Ross controls voting and investment decisions over the Issuer's shares held by the Fund III Entities by majority vote. Each of Fund III GP, ILSF General Partner, and each member of the investment committee of ILSF General Partner disclaims beneficial ownership over the Shares held by the Fund III Entities except to the extent of any pecuniary interest therein. Read SEC document |
| October 01, 2018 Filed Oct 1, 2018 17:28 UTC |
SVLSF V, LLC10% owner
ILSF III, LLC10% owner
SV Life Sciences Fund V (GP), LP10% owner
SV LIFE SCIENCES FUND V LP10% owner
|
ConversionSeries C Preferred Stock · Derivative | 64,815 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-052851 · doc4.xml · derivative · entry 24 SVLSF V, LLC · CIK 0001644160 · 10% owner ILSF III, LLC · CIK 0001630791 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III (GP), L.P. · CIK 0001630790 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III STRATEGIC PARTNERS, L.P. · CIK 0001233226 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III CO-INVESTMENT, L.P. · CIK 0001233315 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III (LP1), L.P. · CIK 0001172861 · 10% owner SV Life Sciences Fund V (GP), LP · CIK 0001644146 · 10% owner SV LIFE SCIENCES FUND V LP · CIK 0001460732 · 10% owner SV Life Sciences Fund V Strategic Partners, L.P. · CIK 0001482194 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By International Life Sciences Fund III Co-Investment, L.P. Disclosed balance after: 0 Underlying: Common Stock · 2,399 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each share of the issuer's Series C Preferred Stock automatically converted into 0.0370 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date. F4 · derivative.exercise_date: Each share of the issuer's Series C Preferred Stock automatically converted into 0.0370 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date. F4 · derivative.expiration_date: Each share of the issuer's Series C Preferred Stock automatically converted into 0.0370 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date. F2 · ownership.nature: International Life Sciences Fund III (GP), LP. ("Fund III GP") is the general partner of each of: (i) International Life Sciences Fund III (LP1), L.P. ("ILSF LP1"), (ii) International Life Sciences Fund III Co-Investment, L.P. ("ILSF Co-Invest") and (iii) International Life Sciences Fund III Strategic Partners, L.P. ("ILSF Strategic" and collectively, the "Fund III Entities"). ILSF III, LLC (the "ILSF General Partner") is the general partner of Fund III GP and, through an investment committee comprised of James Garvey, Kate Bingham, Eugene D. Hill, III and Michael J. Ross controls voting and investment decisions over the Issuer's shares held by the Fund III Entities by majority vote. Each of Fund III GP, ILSF General Partner, and each member of the investment committee of ILSF General Partner disclaims beneficial ownership over the Shares held by the Fund III Entities except to the extent of any pecuniary interest therein. Read SEC document |
| October 01, 2018 Filed Oct 1, 2018 17:28 UTC |
SVLSF V, LLC10% owner
ILSF III, LLC10% owner
SV Life Sciences Fund V (GP), LP10% owner
SV LIFE SCIENCES FUND V LP10% owner
|
ConversionSeries B Preferred Stock · Derivative | 131,683 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-052851 · doc4.xml · derivative · entry 23 SVLSF V, LLC · CIK 0001644160 · 10% owner ILSF III, LLC · CIK 0001630791 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III (GP), L.P. · CIK 0001630790 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III STRATEGIC PARTNERS, L.P. · CIK 0001233226 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III CO-INVESTMENT, L.P. · CIK 0001233315 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III (LP1), L.P. · CIK 0001172861 · 10% owner SV Life Sciences Fund V (GP), LP · CIK 0001644146 · 10% owner SV LIFE SCIENCES FUND V LP · CIK 0001460732 · 10% owner SV Life Sciences Fund V Strategic Partners, L.P. · CIK 0001482194 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By International Life Sciences Fund III Co-Investment, L.P. Disclosed balance after: 0 Underlying: Common Stock · 7,610 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each share of the issuer's Series B Preferred Stock automatically converted into 0.0578 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date. F3 · derivative.exercise_date: Each share of the issuer's Series B Preferred Stock automatically converted into 0.0578 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date. F3 · derivative.expiration_date: Each share of the issuer's Series B Preferred Stock automatically converted into 0.0578 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date. F2 · ownership.nature: International Life Sciences Fund III (GP), LP. ("Fund III GP") is the general partner of each of: (i) International Life Sciences Fund III (LP1), L.P. ("ILSF LP1"), (ii) International Life Sciences Fund III Co-Investment, L.P. ("ILSF Co-Invest") and (iii) International Life Sciences Fund III Strategic Partners, L.P. ("ILSF Strategic" and collectively, the "Fund III Entities"). ILSF III, LLC (the "ILSF General Partner") is the general partner of Fund III GP and, through an investment committee comprised of James Garvey, Kate Bingham, Eugene D. Hill, III and Michael J. Ross controls voting and investment decisions over the Issuer's shares held by the Fund III Entities by majority vote. Each of Fund III GP, ILSF General Partner, and each member of the investment committee of ILSF General Partner disclaims beneficial ownership over the Shares held by the Fund III Entities except to the extent of any pecuniary interest therein. Read SEC document |
| October 01, 2018 Filed Oct 1, 2018 17:28 UTC |
SVLSF V, LLC10% owner
ILSF III, LLC10% owner
SV Life Sciences Fund V (GP), LP10% owner
SV LIFE SCIENCES FUND V LP10% owner
|
ConversionSeries A Preferred Stock · Derivative | 21,776 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-052851 · doc4.xml · derivative · entry 22 SVLSF V, LLC · CIK 0001644160 · 10% owner ILSF III, LLC · CIK 0001630791 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III (GP), L.P. · CIK 0001630790 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III STRATEGIC PARTNERS, L.P. · CIK 0001233226 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III CO-INVESTMENT, L.P. · CIK 0001233315 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III (LP1), L.P. · CIK 0001172861 · 10% owner SV Life Sciences Fund V (GP), LP · CIK 0001644146 · 10% owner SV LIFE SCIENCES FUND V LP · CIK 0001460732 · 10% owner SV Life Sciences Fund V Strategic Partners, L.P. · CIK 0001482194 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By International Life Sciences Fund III Co-Investment, L.P. Disclosed balance after: 0 Underlying: Common Stock · 943 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of the issuer's Series A Preferred Stock automatically converted into 0.0433 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its firm commitment initial public offering (the "IPO") pursuant to a registration statement on Form S-1 (File No. 333-227103) under the Securities Act of 1933, as amended (the "Registration Statement"), and had no expiration date. F1 · derivative.exercise_date: Each share of the issuer's Series A Preferred Stock automatically converted into 0.0433 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its firm commitment initial public offering (the "IPO") pursuant to a registration statement on Form S-1 (File No. 333-227103) under the Securities Act of 1933, as amended (the "Registration Statement"), and had no expiration date. F1 · derivative.expiration_date: Each share of the issuer's Series A Preferred Stock automatically converted into 0.0433 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its firm commitment initial public offering (the "IPO") pursuant to a registration statement on Form S-1 (File No. 333-227103) under the Securities Act of 1933, as amended (the "Registration Statement"), and had no expiration date. F2 · ownership.nature: International Life Sciences Fund III (GP), LP. ("Fund III GP") is the general partner of each of: (i) International Life Sciences Fund III (LP1), L.P. ("ILSF LP1"), (ii) International Life Sciences Fund III Co-Investment, L.P. ("ILSF Co-Invest") and (iii) International Life Sciences Fund III Strategic Partners, L.P. ("ILSF Strategic" and collectively, the "Fund III Entities"). ILSF III, LLC (the "ILSF General Partner") is the general partner of Fund III GP and, through an investment committee comprised of James Garvey, Kate Bingham, Eugene D. Hill, III and Michael J. Ross controls voting and investment decisions over the Issuer's shares held by the Fund III Entities by majority vote. Each of Fund III GP, ILSF General Partner, and each member of the investment committee of ILSF General Partner disclaims beneficial ownership over the Shares held by the Fund III Entities except to the extent of any pecuniary interest therein. Read SEC document |
| October 01, 2018 Filed Oct 1, 2018 17:28 UTC |
SVLSF V, LLC10% owner
ILSF III, LLC10% owner
SV Life Sciences Fund V (GP), LP10% owner
SV LIFE SCIENCES FUND V LP10% owner
|
ConversionCommon Stock | 5,320 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-052851 · doc4.xml · nonDerivative · entry 15 SVLSF V, LLC · CIK 0001644160 · 10% owner ILSF III, LLC · CIK 0001630791 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III (GP), L.P. · CIK 0001630790 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III STRATEGIC PARTNERS, L.P. · CIK 0001233226 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III CO-INVESTMENT, L.P. · CIK 0001233315 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III (LP1), L.P. · CIK 0001172861 · 10% owner SV Life Sciences Fund V (GP), LP · CIK 0001644146 · 10% owner SV LIFE SCIENCES FUND V LP · CIK 0001460732 · 10% owner SV Life Sciences Fund V Strategic Partners, L.P. · CIK 0001482194 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By SV Life Sciences Fund V Strategic Partners, L.P. Disclosed balance after: 18,248 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · price: Each share of the issuer's Series E Preferred Stock automatically converted into 0.0275 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date. F8 · ownership.nature: These shares are owned directly by SV Life Sciences Fund V Strategic Partners, L.P. ("SVLS V SPP"). SVLS V GP is the general partner of SVLS V SPP. The general partner of SVLS V GP is SVLSF V, LLC. Kate Bingham, James Garvey, Eugene D. Hill, III and Michael J. Ross are members of the investment committee of SVLSF V, LLC. SVLS V GP, SVLSF V, LLC and each of the individuals comprising the SVLSF V, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V SPP. Each of SVLS V GP, SVLSF V, LLC and the individual members of the SVLSF V, LLC investment committee disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein. Read SEC document |
| October 01, 2018 Filed Oct 1, 2018 17:28 UTC |
SVLSF V, LLC10% owner
ILSF III, LLC10% owner
SV Life Sciences Fund V (GP), LP10% owner
SV LIFE SCIENCES FUND V LP10% owner
|
ConversionCommon Stock | 5,721 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-052851 · doc4.xml · nonDerivative · entry 14 SVLSF V, LLC · CIK 0001644160 · 10% owner ILSF III, LLC · CIK 0001630791 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III (GP), L.P. · CIK 0001630790 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III STRATEGIC PARTNERS, L.P. · CIK 0001233226 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III CO-INVESTMENT, L.P. · CIK 0001233315 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III (LP1), L.P. · CIK 0001172861 · 10% owner SV Life Sciences Fund V (GP), LP · CIK 0001644146 · 10% owner SV LIFE SCIENCES FUND V LP · CIK 0001460732 · 10% owner SV Life Sciences Fund V Strategic Partners, L.P. · CIK 0001482194 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By SV Life Sciences Fund V Strategic Partners, L.P. Disclosed balance after: 12,928 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · price: Each share of the issuer's Series D Preferred Stock automatically converted into 0.0405 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date. F8 · ownership.nature: These shares are owned directly by SV Life Sciences Fund V Strategic Partners, L.P. ("SVLS V SPP"). SVLS V GP is the general partner of SVLS V SPP. The general partner of SVLS V GP is SVLSF V, LLC. Kate Bingham, James Garvey, Eugene D. Hill, III and Michael J. Ross are members of the investment committee of SVLSF V, LLC. SVLS V GP, SVLSF V, LLC and each of the individuals comprising the SVLSF V, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V SPP. Each of SVLS V GP, SVLSF V, LLC and the individual members of the SVLSF V, LLC investment committee disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein. Read SEC document |
| October 01, 2018 Filed Oct 1, 2018 17:28 UTC |
SVLSF V, LLC10% owner
ILSF III, LLC10% owner
SV Life Sciences Fund V (GP), LP10% owner
SV LIFE SCIENCES FUND V LP10% owner
|
ConversionCommon Stock | 7,207 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-052851 · doc4.xml · nonDerivative · entry 13 SVLSF V, LLC · CIK 0001644160 · 10% owner ILSF III, LLC · CIK 0001630791 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III (GP), L.P. · CIK 0001630790 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III STRATEGIC PARTNERS, L.P. · CIK 0001233226 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III CO-INVESTMENT, L.P. · CIK 0001233315 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III (LP1), L.P. · CIK 0001172861 · 10% owner SV Life Sciences Fund V (GP), LP · CIK 0001644146 · 10% owner SV LIFE SCIENCES FUND V LP · CIK 0001460732 · 10% owner SV Life Sciences Fund V Strategic Partners, L.P. · CIK 0001482194 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By SV Life Sciences Fund V Strategic Partners, L.P. Disclosed balance after: 7,207 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · price: Each share of the issuer's Series C Preferred Stock automatically converted into 0.0370 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date. F8 · ownership.nature: These shares are owned directly by SV Life Sciences Fund V Strategic Partners, L.P. ("SVLS V SPP"). SVLS V GP is the general partner of SVLS V SPP. The general partner of SVLS V GP is SVLSF V, LLC. Kate Bingham, James Garvey, Eugene D. Hill, III and Michael J. Ross are members of the investment committee of SVLSF V, LLC. SVLS V GP, SVLSF V, LLC and each of the individuals comprising the SVLSF V, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V SPP. Each of SVLS V GP, SVLSF V, LLC and the individual members of the SVLSF V, LLC investment committee disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein. Read SEC document |
| October 01, 2018 Filed Oct 1, 2018 17:28 UTC |
SVLSF V, LLC10% owner
ILSF III, LLC10% owner
SV Life Sciences Fund V (GP), LP10% owner
SV LIFE SCIENCES FUND V LP10% owner
|
ConversionCommon Stock | 251,783 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-052851 · doc4.xml · nonDerivative · entry 12 SVLSF V, LLC · CIK 0001644160 · 10% owner ILSF III, LLC · CIK 0001630791 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III (GP), L.P. · CIK 0001630790 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III STRATEGIC PARTNERS, L.P. · CIK 0001233226 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III CO-INVESTMENT, L.P. · CIK 0001233315 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III (LP1), L.P. · CIK 0001172861 · 10% owner SV Life Sciences Fund V (GP), LP · CIK 0001644146 · 10% owner SV LIFE SCIENCES FUND V LP · CIK 0001460732 · 10% owner SV Life Sciences Fund V Strategic Partners, L.P. · CIK 0001482194 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By SV Life Sciences Fund V, L.P. Disclosed balance after: 863,503 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · price: Each share of the issuer's Series E Preferred Stock automatically converted into 0.0275 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date. F5 · ownership.nature: These shares are owned directly by SV Life Sciences Fund V, L.P. ("SVLS V LP"). SV Life Sciences Fund V (GP), LP ("SVLS V GP") is the general partner of SVLS V LP. The general partner of SVLS V GP is SVLSF V, LLC. Kate Bingham, James Garvey, Eugene D. Hill, III and Michael J. Ross are members of the investment committee of SVLSF V, LLC. SVLS V GP, SVLSF V, LLC and each of the individuals comprising the SVLSF V, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V LP. Each of SVLS V GP, SVLSF V, LLC and the individual members of the SVLSF V, LLC investment committee disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein. Read SEC document |
| October 01, 2018 Filed Oct 1, 2018 17:28 UTC |
SVLSF V, LLC10% owner
ILSF III, LLC10% owner
SV Life Sciences Fund V (GP), LP10% owner
SV LIFE SCIENCES FUND V LP10% owner
|
ConversionCommon Stock | 270,690 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-052851 · doc4.xml · nonDerivative · entry 11 SVLSF V, LLC · CIK 0001644160 · 10% owner ILSF III, LLC · CIK 0001630791 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III (GP), L.P. · CIK 0001630790 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III STRATEGIC PARTNERS, L.P. · CIK 0001233226 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III CO-INVESTMENT, L.P. · CIK 0001233315 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III (LP1), L.P. · CIK 0001172861 · 10% owner SV Life Sciences Fund V (GP), LP · CIK 0001644146 · 10% owner SV LIFE SCIENCES FUND V LP · CIK 0001460732 · 10% owner SV Life Sciences Fund V Strategic Partners, L.P. · CIK 0001482194 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By SV Life Sciences Fund V, L.P. Disclosed balance after: 611,720 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · price: Each share of the issuer's Series D Preferred Stock automatically converted into 0.0405 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date. F5 · ownership.nature: These shares are owned directly by SV Life Sciences Fund V, L.P. ("SVLS V LP"). SV Life Sciences Fund V (GP), LP ("SVLS V GP") is the general partner of SVLS V LP. The general partner of SVLS V GP is SVLSF V, LLC. Kate Bingham, James Garvey, Eugene D. Hill, III and Michael J. Ross are members of the investment committee of SVLSF V, LLC. SVLS V GP, SVLSF V, LLC and each of the individuals comprising the SVLSF V, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V LP. Each of SVLS V GP, SVLSF V, LLC and the individual members of the SVLSF V, LLC investment committee disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein. Read SEC document |
| October 01, 2018 Filed Oct 1, 2018 17:28 UTC |
SVLSF V, LLC10% owner
ILSF III, LLC10% owner
SV Life Sciences Fund V (GP), LP10% owner
SV LIFE SCIENCES FUND V LP10% owner
|
ConversionCommon Stock | 341,030 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-052851 · doc4.xml · nonDerivative · entry 10 SVLSF V, LLC · CIK 0001644160 · 10% owner ILSF III, LLC · CIK 0001630791 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III (GP), L.P. · CIK 0001630790 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III STRATEGIC PARTNERS, L.P. · CIK 0001233226 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III CO-INVESTMENT, L.P. · CIK 0001233315 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III (LP1), L.P. · CIK 0001172861 · 10% owner SV Life Sciences Fund V (GP), LP · CIK 0001644146 · 10% owner SV LIFE SCIENCES FUND V LP · CIK 0001460732 · 10% owner SV Life Sciences Fund V Strategic Partners, L.P. · CIK 0001482194 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By SV Life Sciences Fund V, L.P. Disclosed balance after: 341,030 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · price: Each share of the issuer's Series C Preferred Stock automatically converted into 0.0370 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date. F5 · ownership.nature: These shares are owned directly by SV Life Sciences Fund V, L.P. ("SVLS V LP"). SV Life Sciences Fund V (GP), LP ("SVLS V GP") is the general partner of SVLS V LP. The general partner of SVLS V GP is SVLSF V, LLC. Kate Bingham, James Garvey, Eugene D. Hill, III and Michael J. Ross are members of the investment committee of SVLSF V, LLC. SVLS V GP, SVLSF V, LLC and each of the individuals comprising the SVLSF V, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V LP. Each of SVLS V GP, SVLSF V, LLC and the individual members of the SVLSF V, LLC investment committee disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein. Read SEC document |
| October 01, 2018 Filed Oct 1, 2018 17:28 UTC |
SVLSF V, LLC10% owner
ILSF III, LLC10% owner
SV Life Sciences Fund V (GP), LP10% owner
SV LIFE SCIENCES FUND V LP10% owner
|
ConversionCommon Stock | 1,931 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-052851 · doc4.xml · nonDerivative · entry 9 SVLSF V, LLC · CIK 0001644160 · 10% owner ILSF III, LLC · CIK 0001630791 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III (GP), L.P. · CIK 0001630790 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III STRATEGIC PARTNERS, L.P. · CIK 0001233226 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III CO-INVESTMENT, L.P. · CIK 0001233315 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III (LP1), L.P. · CIK 0001172861 · 10% owner SV Life Sciences Fund V (GP), LP · CIK 0001644146 · 10% owner SV LIFE SCIENCES FUND V LP · CIK 0001460732 · 10% owner SV Life Sciences Fund V Strategic Partners, L.P. · CIK 0001482194 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By International Life Sciences Fund III Strategic Partners, L.P. Disclosed balance after: 8,817 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · price: Each share of the issuer's Series C Preferred Stock automatically converted into 0.0370 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date. F2 · ownership.nature: International Life Sciences Fund III (GP), LP. ("Fund III GP") is the general partner of each of: (i) International Life Sciences Fund III (LP1), L.P. ("ILSF LP1"), (ii) International Life Sciences Fund III Co-Investment, L.P. ("ILSF Co-Invest") and (iii) International Life Sciences Fund III Strategic Partners, L.P. ("ILSF Strategic" and collectively, the "Fund III Entities"). ILSF III, LLC (the "ILSF General Partner") is the general partner of Fund III GP and, through an investment committee comprised of James Garvey, Kate Bingham, Eugene D. Hill, III and Michael J. Ross controls voting and investment decisions over the Issuer's shares held by the Fund III Entities by majority vote. Each of Fund III GP, ILSF General Partner, and each member of the investment committee of ILSF General Partner disclaims beneficial ownership over the Shares held by the Fund III Entities except to the extent of any pecuniary interest therein. Read SEC document |
| October 01, 2018 Filed Oct 1, 2018 17:28 UTC |
SVLSF V, LLC10% owner
ILSF III, LLC10% owner
SV Life Sciences Fund V (GP), LP10% owner
SV LIFE SCIENCES FUND V LP10% owner
|
ConversionCommon Stock | 6,128 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-052851 · doc4.xml · nonDerivative · entry 8 SVLSF V, LLC · CIK 0001644160 · 10% owner ILSF III, LLC · CIK 0001630791 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III (GP), L.P. · CIK 0001630790 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III STRATEGIC PARTNERS, L.P. · CIK 0001233226 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III CO-INVESTMENT, L.P. · CIK 0001233315 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III (LP1), L.P. · CIK 0001172861 · 10% owner SV Life Sciences Fund V (GP), LP · CIK 0001644146 · 10% owner SV LIFE SCIENCES FUND V LP · CIK 0001460732 · 10% owner SV Life Sciences Fund V Strategic Partners, L.P. · CIK 0001482194 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By International Life Sciences Fund III Strategic Partners, L.P. Disclosed balance after: 6,886 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Each share of the issuer's Series B Preferred Stock automatically converted into 0.0578 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date. F2 · ownership.nature: International Life Sciences Fund III (GP), LP. ("Fund III GP") is the general partner of each of: (i) International Life Sciences Fund III (LP1), L.P. ("ILSF LP1"), (ii) International Life Sciences Fund III Co-Investment, L.P. ("ILSF Co-Invest") and (iii) International Life Sciences Fund III Strategic Partners, L.P. ("ILSF Strategic" and collectively, the "Fund III Entities"). ILSF III, LLC (the "ILSF General Partner") is the general partner of Fund III GP and, through an investment committee comprised of James Garvey, Kate Bingham, Eugene D. Hill, III and Michael J. Ross controls voting and investment decisions over the Issuer's shares held by the Fund III Entities by majority vote. Each of Fund III GP, ILSF General Partner, and each member of the investment committee of ILSF General Partner disclaims beneficial ownership over the Shares held by the Fund III Entities except to the extent of any pecuniary interest therein. Read SEC document |
| October 01, 2018 Filed Oct 1, 2018 17:28 UTC |
SVLSF V, LLC10% owner
ILSF III, LLC10% owner
SV Life Sciences Fund V (GP), LP10% owner
SV LIFE SCIENCES FUND V LP10% owner
|
ConversionCommon Stock | 758 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-052851 · doc4.xml · nonDerivative · entry 7 SVLSF V, LLC · CIK 0001644160 · 10% owner ILSF III, LLC · CIK 0001630791 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III (GP), L.P. · CIK 0001630790 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III STRATEGIC PARTNERS, L.P. · CIK 0001233226 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III CO-INVESTMENT, L.P. · CIK 0001233315 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III (LP1), L.P. · CIK 0001172861 · 10% owner SV Life Sciences Fund V (GP), LP · CIK 0001644146 · 10% owner SV LIFE SCIENCES FUND V LP · CIK 0001460732 · 10% owner SV Life Sciences Fund V Strategic Partners, L.P. · CIK 0001482194 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By International Life Sciences Fund III Strategic Partners, L.P. Disclosed balance after: 758 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of the issuer's Series A Preferred Stock automatically converted into 0.0433 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its firm commitment initial public offering (the "IPO") pursuant to a registration statement on Form S-1 (File No. 333-227103) under the Securities Act of 1933, as amended (the "Registration Statement"), and had no expiration date. F2 · ownership.nature: International Life Sciences Fund III (GP), LP. ("Fund III GP") is the general partner of each of: (i) International Life Sciences Fund III (LP1), L.P. ("ILSF LP1"), (ii) International Life Sciences Fund III Co-Investment, L.P. ("ILSF Co-Invest") and (iii) International Life Sciences Fund III Strategic Partners, L.P. ("ILSF Strategic" and collectively, the "Fund III Entities"). ILSF III, LLC (the "ILSF General Partner") is the general partner of Fund III GP and, through an investment committee comprised of James Garvey, Kate Bingham, Eugene D. Hill, III and Michael J. Ross controls voting and investment decisions over the Issuer's shares held by the Fund III Entities by majority vote. Each of Fund III GP, ILSF General Partner, and each member of the investment committee of ILSF General Partner disclaims beneficial ownership over the Shares held by the Fund III Entities except to the extent of any pecuniary interest therein. Read SEC document |
| October 01, 2018 Filed Oct 1, 2018 17:28 UTC |
SVLSF V, LLC10% owner
ILSF III, LLC10% owner
SV Life Sciences Fund V (GP), LP10% owner
SV LIFE SCIENCES FUND V LP10% owner
|
ConversionCommon Stock | 202,115 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-052851 · doc4.xml · nonDerivative · entry 6 SVLSF V, LLC · CIK 0001644160 · 10% owner ILSF III, LLC · CIK 0001630791 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III (GP), L.P. · CIK 0001630790 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III STRATEGIC PARTNERS, L.P. · CIK 0001233226 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III CO-INVESTMENT, L.P. · CIK 0001233315 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III (LP1), L.P. · CIK 0001172861 · 10% owner SV Life Sciences Fund V (GP), LP · CIK 0001644146 · 10% owner SV LIFE SCIENCES FUND V LP · CIK 0001460732 · 10% owner SV Life Sciences Fund V Strategic Partners, L.P. · CIK 0001482194 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By International Life Sciences Fund III (LP1), L.P. Disclosed balance after: 923,022 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · price: Each share of the issuer's Series C Preferred Stock automatically converted into 0.0370 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date. F2 · ownership.nature: International Life Sciences Fund III (GP), LP. ("Fund III GP") is the general partner of each of: (i) International Life Sciences Fund III (LP1), L.P. ("ILSF LP1"), (ii) International Life Sciences Fund III Co-Investment, L.P. ("ILSF Co-Invest") and (iii) International Life Sciences Fund III Strategic Partners, L.P. ("ILSF Strategic" and collectively, the "Fund III Entities"). ILSF III, LLC (the "ILSF General Partner") is the general partner of Fund III GP and, through an investment committee comprised of James Garvey, Kate Bingham, Eugene D. Hill, III and Michael J. Ross controls voting and investment decisions over the Issuer's shares held by the Fund III Entities by majority vote. Each of Fund III GP, ILSF General Partner, and each member of the investment committee of ILSF General Partner disclaims beneficial ownership over the Shares held by the Fund III Entities except to the extent of any pecuniary interest therein. Read SEC document |
| October 01, 2018 Filed Oct 1, 2018 17:28 UTC |
SVLSF V, LLC10% owner
ILSF III, LLC10% owner
SV Life Sciences Fund V (GP), LP10% owner
SV LIFE SCIENCES FUND V LP10% owner
|
ConversionCommon Stock | 641,440 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-052851 · doc4.xml · nonDerivative · entry 5 SVLSF V, LLC · CIK 0001644160 · 10% owner ILSF III, LLC · CIK 0001630791 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III (GP), L.P. · CIK 0001630790 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III STRATEGIC PARTNERS, L.P. · CIK 0001233226 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III CO-INVESTMENT, L.P. · CIK 0001233315 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III (LP1), L.P. · CIK 0001172861 · 10% owner SV Life Sciences Fund V (GP), LP · CIK 0001644146 · 10% owner SV LIFE SCIENCES FUND V LP · CIK 0001460732 · 10% owner SV Life Sciences Fund V Strategic Partners, L.P. · CIK 0001482194 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By International Life Sciences Fund III (LP1), L.P. Disclosed balance after: 720,907 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Each share of the issuer's Series B Preferred Stock automatically converted into 0.0578 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date. F2 · ownership.nature: International Life Sciences Fund III (GP), LP. ("Fund III GP") is the general partner of each of: (i) International Life Sciences Fund III (LP1), L.P. ("ILSF LP1"), (ii) International Life Sciences Fund III Co-Investment, L.P. ("ILSF Co-Invest") and (iii) International Life Sciences Fund III Strategic Partners, L.P. ("ILSF Strategic" and collectively, the "Fund III Entities"). ILSF III, LLC (the "ILSF General Partner") is the general partner of Fund III GP and, through an investment committee comprised of James Garvey, Kate Bingham, Eugene D. Hill, III and Michael J. Ross controls voting and investment decisions over the Issuer's shares held by the Fund III Entities by majority vote. Each of Fund III GP, ILSF General Partner, and each member of the investment committee of ILSF General Partner disclaims beneficial ownership over the Shares held by the Fund III Entities except to the extent of any pecuniary interest therein. Read SEC document |
| October 01, 2018 Filed Oct 1, 2018 17:28 UTC |
SVLSF V, LLC10% owner
ILSF III, LLC10% owner
SV Life Sciences Fund V (GP), LP10% owner
SV LIFE SCIENCES FUND V LP10% owner
|
ConversionCommon Stock | 79,467 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-052851 · doc4.xml · nonDerivative · entry 4 SVLSF V, LLC · CIK 0001644160 · 10% owner ILSF III, LLC · CIK 0001630791 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III (GP), L.P. · CIK 0001630790 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III STRATEGIC PARTNERS, L.P. · CIK 0001233226 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III CO-INVESTMENT, L.P. · CIK 0001233315 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III (LP1), L.P. · CIK 0001172861 · 10% owner SV Life Sciences Fund V (GP), LP · CIK 0001644146 · 10% owner SV LIFE SCIENCES FUND V LP · CIK 0001460732 · 10% owner SV Life Sciences Fund V Strategic Partners, L.P. · CIK 0001482194 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By International Life Sciences Fund III (LP1), L.P. Disclosed balance after: 79,467 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of the issuer's Series A Preferred Stock automatically converted into 0.0433 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its firm commitment initial public offering (the "IPO") pursuant to a registration statement on Form S-1 (File No. 333-227103) under the Securities Act of 1933, as amended (the "Registration Statement"), and had no expiration date. F2 · ownership.nature: International Life Sciences Fund III (GP), LP. ("Fund III GP") is the general partner of each of: (i) International Life Sciences Fund III (LP1), L.P. ("ILSF LP1"), (ii) International Life Sciences Fund III Co-Investment, L.P. ("ILSF Co-Invest") and (iii) International Life Sciences Fund III Strategic Partners, L.P. ("ILSF Strategic" and collectively, the "Fund III Entities"). ILSF III, LLC (the "ILSF General Partner") is the general partner of Fund III GP and, through an investment committee comprised of James Garvey, Kate Bingham, Eugene D. Hill, III and Michael J. Ross controls voting and investment decisions over the Issuer's shares held by the Fund III Entities by majority vote. Each of Fund III GP, ILSF General Partner, and each member of the investment committee of ILSF General Partner disclaims beneficial ownership over the Shares held by the Fund III Entities except to the extent of any pecuniary interest therein. Read SEC document |
| October 01, 2018 Filed Oct 1, 2018 17:28 UTC |
SVLSF V, LLC10% owner
ILSF III, LLC10% owner
SV Life Sciences Fund V (GP), LP10% owner
SV LIFE SCIENCES FUND V LP10% owner
|
ConversionCommon Stock | 2,399 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-052851 · doc4.xml · nonDerivative · entry 3 SVLSF V, LLC · CIK 0001644160 · 10% owner ILSF III, LLC · CIK 0001630791 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III (GP), L.P. · CIK 0001630790 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III STRATEGIC PARTNERS, L.P. · CIK 0001233226 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III CO-INVESTMENT, L.P. · CIK 0001233315 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III (LP1), L.P. · CIK 0001172861 · 10% owner SV Life Sciences Fund V (GP), LP · CIK 0001644146 · 10% owner SV LIFE SCIENCES FUND V LP · CIK 0001460732 · 10% owner SV Life Sciences Fund V Strategic Partners, L.P. · CIK 0001482194 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By International Life Sciences Fund III Co-Investment, L.P. Disclosed balance after: 10,952 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · price: Each share of the issuer's Series C Preferred Stock automatically converted into 0.0370 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date. F2 · ownership.nature: International Life Sciences Fund III (GP), LP. ("Fund III GP") is the general partner of each of: (i) International Life Sciences Fund III (LP1), L.P. ("ILSF LP1"), (ii) International Life Sciences Fund III Co-Investment, L.P. ("ILSF Co-Invest") and (iii) International Life Sciences Fund III Strategic Partners, L.P. ("ILSF Strategic" and collectively, the "Fund III Entities"). ILSF III, LLC (the "ILSF General Partner") is the general partner of Fund III GP and, through an investment committee comprised of James Garvey, Kate Bingham, Eugene D. Hill, III and Michael J. Ross controls voting and investment decisions over the Issuer's shares held by the Fund III Entities by majority vote. Each of Fund III GP, ILSF General Partner, and each member of the investment committee of ILSF General Partner disclaims beneficial ownership over the Shares held by the Fund III Entities except to the extent of any pecuniary interest therein. Read SEC document |
| October 01, 2018 Filed Oct 1, 2018 17:28 UTC |
SVLSF V, LLC10% owner
ILSF III, LLC10% owner
SV Life Sciences Fund V (GP), LP10% owner
SV LIFE SCIENCES FUND V LP10% owner
|
ConversionCommon Stock | 7,610 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-052851 · doc4.xml · nonDerivative · entry 2 SVLSF V, LLC · CIK 0001644160 · 10% owner ILSF III, LLC · CIK 0001630791 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III (GP), L.P. · CIK 0001630790 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III STRATEGIC PARTNERS, L.P. · CIK 0001233226 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III CO-INVESTMENT, L.P. · CIK 0001233315 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III (LP1), L.P. · CIK 0001172861 · 10% owner SV Life Sciences Fund V (GP), LP · CIK 0001644146 · 10% owner SV LIFE SCIENCES FUND V LP · CIK 0001460732 · 10% owner SV Life Sciences Fund V Strategic Partners, L.P. · CIK 0001482194 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By International Life Sciences Fund III Co-Investment, L.P. Disclosed balance after: 8,553 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Each share of the issuer's Series B Preferred Stock automatically converted into 0.0578 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date. F2 · ownership.nature: International Life Sciences Fund III (GP), LP. ("Fund III GP") is the general partner of each of: (i) International Life Sciences Fund III (LP1), L.P. ("ILSF LP1"), (ii) International Life Sciences Fund III Co-Investment, L.P. ("ILSF Co-Invest") and (iii) International Life Sciences Fund III Strategic Partners, L.P. ("ILSF Strategic" and collectively, the "Fund III Entities"). ILSF III, LLC (the "ILSF General Partner") is the general partner of Fund III GP and, through an investment committee comprised of James Garvey, Kate Bingham, Eugene D. Hill, III and Michael J. Ross controls voting and investment decisions over the Issuer's shares held by the Fund III Entities by majority vote. Each of Fund III GP, ILSF General Partner, and each member of the investment committee of ILSF General Partner disclaims beneficial ownership over the Shares held by the Fund III Entities except to the extent of any pecuniary interest therein. Read SEC document |
| October 01, 2018 Filed Oct 1, 2018 17:28 UTC |
SVLSF V, LLC10% owner
ILSF III, LLC10% owner
SV Life Sciences Fund V (GP), LP10% owner
SV LIFE SCIENCES FUND V LP10% owner
|
ConversionCommon Stock | 943 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-052851 · doc4.xml · nonDerivative · entry 1 SVLSF V, LLC · CIK 0001644160 · 10% owner ILSF III, LLC · CIK 0001630791 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III (GP), L.P. · CIK 0001630790 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III STRATEGIC PARTNERS, L.P. · CIK 0001233226 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III CO-INVESTMENT, L.P. · CIK 0001233315 · 10% owner INTERNATIONAL LIFE SCIENCES FUND III (LP1), L.P. · CIK 0001172861 · 10% owner SV Life Sciences Fund V (GP), LP · CIK 0001644146 · 10% owner SV LIFE SCIENCES FUND V LP · CIK 0001460732 · 10% owner SV Life Sciences Fund V Strategic Partners, L.P. · CIK 0001482194 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By International Life Sciences Fund III Co-Investment, L.P. Disclosed balance after: 943 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of the issuer's Series A Preferred Stock automatically converted into 0.0433 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its firm commitment initial public offering (the "IPO") pursuant to a registration statement on Form S-1 (File No. 333-227103) under the Securities Act of 1933, as amended (the "Registration Statement"), and had no expiration date. F2 · ownership.nature: International Life Sciences Fund III (GP), LP. ("Fund III GP") is the general partner of each of: (i) International Life Sciences Fund III (LP1), L.P. ("ILSF LP1"), (ii) International Life Sciences Fund III Co-Investment, L.P. ("ILSF Co-Invest") and (iii) International Life Sciences Fund III Strategic Partners, L.P. ("ILSF Strategic" and collectively, the "Fund III Entities"). ILSF III, LLC (the "ILSF General Partner") is the general partner of Fund III GP and, through an investment committee comprised of James Garvey, Kate Bingham, Eugene D. Hill, III and Michael J. Ross controls voting and investment decisions over the Issuer's shares held by the Fund III Entities by majority vote. Each of Fund III GP, ILSF General Partner, and each member of the investment committee of ILSF General Partner disclaims beneficial ownership over the Shares held by the Fund III Entities except to the extent of any pecuniary interest therein. Read SEC document |
| October 01, 2018 Filed Oct 1, 2018 21:15 UTC |
Freund John GordonDirector · 10% owner
|
ConversionSeries E Preferred Stock · Derivative | 18,698,578 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-052835 · doc4.xml · derivative · entry 6 Freund John Gordon · CIK 0001296771 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Skyline Venture Partners V, L.P. Disclosed balance after: 0 Underlying: Common Stock · 514,211 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each share of the issuer's Series E Preferred Stock automatically converted into 0.0275 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date. F4 · derivative.exercise_date: Each share of the issuer's Series E Preferred Stock automatically converted into 0.0275 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date. F4 · derivative.expiration_date: Each share of the issuer's Series E Preferred Stock automatically converted into 0.0275 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date. F2 · ownership.nature: These securities are held of record by Skyline Venture Partners V, L.P. ("Skyline L.P."). Skyline Venture Management V, LLC ("Skyline Management") is the general partner of Skyline L.P. the reporting person, a member of the issuer's board of directors, together with Yasunori Kaneko, are the managing directors of Skyline Management, and each may be deemed to share voting and investment power over the securities held by Skyline L.P. The reporting person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes. Read SEC document |
| October 01, 2018 Filed Oct 1, 2018 21:15 UTC |
Freund John GordonDirector · 10% owner
|
ConversionSeries D Preferred Stock · Derivative | 12,846,023 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-052835 · doc4.xml · derivative · entry 5 Freund John Gordon · CIK 0001296771 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Skyline Venture Partners V, L.P. Disclosed balance after: 0 Underlying: Common Stock · 520,264 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each share of the issuer's Series D Preferred Stock automatically converted into 0.0405 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date. F3 · derivative.exercise_date: Each share of the issuer's Series D Preferred Stock automatically converted into 0.0405 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date. F3 · derivative.expiration_date: Each share of the issuer's Series D Preferred Stock automatically converted into 0.0405 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date. F2 · ownership.nature: These securities are held of record by Skyline Venture Partners V, L.P. ("Skyline L.P."). Skyline Venture Management V, LLC ("Skyline Management") is the general partner of Skyline L.P. the reporting person, a member of the issuer's board of directors, together with Yasunori Kaneko, are the managing directors of Skyline Management, and each may be deemed to share voting and investment power over the securities held by Skyline L.P. The reporting person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes. Read SEC document |
| October 01, 2018 Filed Oct 1, 2018 21:15 UTC |
Freund John GordonDirector · 10% owner
|
ConversionSeries C Preferred Stock · Derivative | 25,015,635 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-052835 · doc4.xml · derivative · entry 4 Freund John Gordon · CIK 0001296771 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Skyline Venture Partners V, L.P. Disclosed balance after: 0 Underlying: Common Stock · 925,578 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of the issuer's Series C Preferred Stock automatically converted into 0.0370 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its firm commitment initial public offering (the "IPO") pursuant to a registration statement on Form S-1 (File No. 333-227103) under the Securities Act of 1933, as amended (the "Registration Statement"), and had no expiration date. F1 · derivative.exercise_date: Each share of the issuer's Series C Preferred Stock automatically converted into 0.0370 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its firm commitment initial public offering (the "IPO") pursuant to a registration statement on Form S-1 (File No. 333-227103) under the Securities Act of 1933, as amended (the "Registration Statement"), and had no expiration date. F1 · derivative.expiration_date: Each share of the issuer's Series C Preferred Stock automatically converted into 0.0370 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its firm commitment initial public offering (the "IPO") pursuant to a registration statement on Form S-1 (File No. 333-227103) under the Securities Act of 1933, as amended (the "Registration Statement"), and had no expiration date. F2 · ownership.nature: These securities are held of record by Skyline Venture Partners V, L.P. ("Skyline L.P."). Skyline Venture Management V, LLC ("Skyline Management") is the general partner of Skyline L.P. the reporting person, a member of the issuer's board of directors, together with Yasunori Kaneko, are the managing directors of Skyline Management, and each may be deemed to share voting and investment power over the securities held by Skyline L.P. The reporting person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes. Read SEC document |
| October 01, 2018 Filed Oct 1, 2018 21:15 UTC |
Freund John GordonDirector · 10% owner
|
ConversionCommon Stock | 514,211 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-052835 · doc4.xml · nonDerivative · entry 3 Freund John Gordon · CIK 0001296771 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Skyline Venture Partners V, L.P. Disclosed balance after: 1,960,053 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · price: Each share of the issuer's Series E Preferred Stock automatically converted into 0.0275 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date. F2 · ownership.nature: These securities are held of record by Skyline Venture Partners V, L.P. ("Skyline L.P."). Skyline Venture Management V, LLC ("Skyline Management") is the general partner of Skyline L.P. the reporting person, a member of the issuer's board of directors, together with Yasunori Kaneko, are the managing directors of Skyline Management, and each may be deemed to share voting and investment power over the securities held by Skyline L.P. The reporting person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.